US5324571083
© PR Newswire
12.12.2025
LLY
LISTED
NYSE
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
News Preview
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated diseaseIn all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and extended time to chemotherapy by more than a yearThese dat...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
LLY
LISTED
NYSE
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
News Preview
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipronCompany plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site announced since 2020 INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) t...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
LLY
LISTED
NYSE
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
News Preview
The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal of Clinical Oncology and highlighted in a late-breaking oral presentation at the 2025 American Society of Hematology Annual Meeting and Exposition,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
08.12.2025
LLY
LISTED
NYSE
Lilly declares first-quarter 2026 dividend
News Preview
INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock.The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026.About LillyLilly is a medicine...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
08.12.2025
LLY
LISTED
NYSE
Carolyn Bertozzi returns to Lilly board of directors
News Preview
INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees."On behalf of Lilly and the entire board, I would like to welcome Carolyn...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2025
LLY
LISTED
NYSE
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
News Preview
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) populationProgression-free survival data were immature but trended in favor of pirtobrutinib with a 43% redu...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2025
LLY
LISTED
NYSE
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
News Preview
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitorThis expanded indication represents a substantial increase in the number of CLL/SLL patients who may benefit from Jaypirca and aligns with the patient population endorsed...
Themefolio
Profiler
Peergroup
© PR Newswire
24.11.2025
LLY
LISTED
NYSE
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
News Preview
Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone and in combination with Verzenio® (abemaciclib) in ER+, HER2– metastatic breast cancer to be presented as a late-breaking oral presentationUpdated safety and efficacy data to be presented from PIKALO-1, the Phase 1/2 trial of Lilly's pan-mutant-selective PI3Kα inhibi...
Themefolio
Profiler
Peergroup
© PR Newswire
24.11.2025
LLY
LISTED
NYSE
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
News Preview
Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve CLL/SLL patients – will be presented as an oral presentationResults from the Phase 3 BRUIN CLL-313 study of pirtobrutinib in patients with treatment-...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
LLY
LISTED
NYSE
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
News Preview
Gateway Labs model provides lab space and tailored scientific engagement to fuel next-generation medicines
New Center City site, in partnership with Breakthrough Properties, will host a select group of early-stage biotech companies...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2025
LLY
LISTED
NYSE
Lilly to participate in Citi's 2025 Global Healthcare Conference
News Preview
INDIANAPOLIS, Nov. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
LLY
LISTED
NYSE
Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
News Preview
New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease
INDIANAPOLIS, Nov. 10, 2025 /PRNewswire/ -- For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and ad...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
06.11.2025
LLY
LISTED
NYSE
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
News Preview
INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and stre...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
LLY
LISTED
NYSE
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
News Preview
Medicare beneficiaries with obesity or overweight will have access to
Zepbound and orforglipron, if approved, at $50 a month
INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with the...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
LLY
LISTED
NYSE
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
News Preview
Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month
INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluatin...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
LLY
LISTED
NYSE
Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
News Preview
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new €2.6 billion (3...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
LLY
LISTED
NYSE
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
News Preview
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufac...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
LLY
LISTED
NYSE
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
News Preview
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
INDIANAPOLIS, Oct. 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today a planned investment of more than $1.2 billion to expand and modernize its Lilly del Ca...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2025
LLY
LISTED
NYSE
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
News Preview
New AI capabilities will help scientists
identify, optimize and validate new molecules
Additional applications include manufacturing, medical imaging and enterprise AI agents
INDIANAPOLIS, Oct...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2025
LLY
LISTED
NYSE
Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact
News Preview
INDIANAPOLIS, Oct. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its roster of Team USA athletes for the Olympic and Paralympic Winter Games Milano Cortina 2026, reaffirming its mission to support athletes' holistic health and translate their achievements into meaningful impact for co...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
LLY
LISTED
NYSE
Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
News Preview
Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen
Omvoh single-injection dosing will be available for U.S. patients in early 2026...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
LLY
LISTED
NYSE
Lilly declares fourth-quarter 2025 dividend
News Preview
INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock.
The dividend is payable on December 10, 2025, to shareholders of record at the close of bus...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
LLY
LISTED
NYSE
Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
News Preview
Basketball legend, entrepreneur and entertainer Shaquille O'Neal partners with Lilly to shine a spotlight on moderate-to-severe obstructive sleep apnea (OSA), encouraging Americans to talk to their doctor
Moderate-to-severe obstructive sleep apnea (OSA) is a ser...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
LLY
LISTED
NYSE
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
News Preview
New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared to approved monthly maintenance dosing
Lilly submitted these data to the FDA for a potential l...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
LLY
LISTED
NYSE
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
News Preview
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer
Seven-year results from the Phase 3 monarchE trial also show Verzenio plus endocrine therap...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
LLY
LISTED
NYSE
Lilly confirms date and conference call for third-quarter 2025 financial results announcement
News Preview
INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. ...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2025
LLY
LISTED
NYSE
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
News Preview
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with
dapagliflozin, meeting the primary endpoint
In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
LLY
LISTED
NYSE
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
News Preview
Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral presentation
Additional presentations showcase Lilly's robust oncology p...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
LLY
LISTED
NYSE
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
News Preview
Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission
At four years, nearly all patients who achieved clinical remission at one y...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2025
LLY
LISTED
NYSE
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
News Preview
New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines
Gateway Labs model provides flexible lab space and tailored scientific engagement to support early-stage biotechs
INDIANAPOLIS, Sept. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the official opening of its...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2025
LLY
LISTED
NYSE
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
News Preview
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline
Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels
INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the E...
Themefolio
Profiler
Peergroup
© PR Newswire
25.09.2025
LLY
LISTED
NYSE
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
News Preview
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC
INDIANAPOLIS, Sept. 25, 2025 /PRNews...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2025
LLY
LISTED
NYSE
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
News Preview
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Company plans to create 4,615 manufacturing and construction jobs
INDIANAPOLIS, Sept. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
LLY
LISTED
NYSE
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
News Preview
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week extension
The safety and tolerability profile of Mounjaro was generally consistent with previous adult studies
INDIANAPOLIS, Sept. 17, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
LLY
LISTED
NYSE
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
News Preview
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses
Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) vs. 11.0 lbs (5.3%) with oral semaglutide, a 73.6% relative improvement, in a key secondary endpoint
The safety and tolerability of orforglipron were...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
LLY
LISTED
NYSE
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
News Preview
The investigational once-daily oral pill led to an average weight loss of 27.3 lbs (12.4%) at the highest dose at week 72 in the Phase 3 study
Orforglipron demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity
INDIANAPOLIS, Sept. 16, 2025 /PR...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
LLY
LISTED
NYSE
Lilly announces plans to build $5 billion manufacturing facility in Virginia
News Preview
New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other advanced therapies
Company will create 2,450 high-wage manufacturing and construction jobs
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
INDIANAPOLIS, Sept. 1...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2025
LLY
LISTED
NYSE
Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
News Preview
INDIANAPOLIS, Sept. 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time.
A live audio webcast will be available on the "Webcas...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
LLY
LISTED
NYSE
Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health
News Preview
Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain health conversations between people and their doctors
Nearly four in five Americans say they would want to know if they have Alzheimer's disease before symptoms interfere with daily activities, highlighting the growing desire...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
LLY
LISTED
NYSE
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
News Preview
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
New offering expands Lilly Catalyze360's support for early-stage drug development
INDIANAPOLIS, Sept. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machi...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2025
LLY
LISTED
NYSE
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
News Preview
In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines
Participants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an average of 22.9 lbs (10.5%) on the highest dose, wi...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
LLY
LISTED
NYSE
Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
INDIANAPOLIS, Aug. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer will take part in a fireside chat at 9:15 a.m...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2025
LLY
LISTED
NYSE
Lilly to participate in Wells Fargo 20th Annual Healthcare Conference
News Preview
INDIANAPOLIS, Aug. 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025. Patrik Jonsson, executive vice president and president of Lilly International, will take part in a fireside chat at 9:30 a.m., Eastern time.
A live audio webcast will be available on...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
LLY
LISTED
NYSE
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
News Preview
INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her r...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
LLY
LISTED
NYSE
Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
News Preview
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa
INDIANAPOLIS and CAIRO, Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
LLY
LISTED
NYSE
Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
News Preview
Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
LLY
LISTED
NYSE
Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
INDIANAPOLIS, Aug. 22, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 5, 2024. Jacob Van Naarden, executive vice president and president, Lilly Oncology, will participate in a fireside chat at 7:45 a.m. Eastern time.
A live audio webcast will be available on...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2024
LLY
LISTED
NYSE
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
News Preview
176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date
Tirzepatide resulted in sustained weight loss through the treatment period, averaging a 22.9% decrease in body weight with the 15 mg dose at end of treatment
Results are consistent with the combined pharmacology of GIP and GLP-1 re...
Themefolio
Profiler
Peergroup
© PR Newswire
16.08.2024
LLY
LISTED
NYSE
Lilly announces retirement of Marschall S. Runge from its Board of Directors
News Preview
INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024.
Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2024
LLY
LISTED
NYSE
Lilly opens state-of-the-art research and development center in the Boston Seaport
News Preview
Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs
New 346,000 square foot facility will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from Lilly Gateway Labs' companies
INDIANAPOLIS, Aug. 13, 2024 /PRN...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2024
LLY
LISTED
NYSE
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
News Preview
Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%. Excluding the sale of rights for Baqsimi, non-incretin revenue increased 17% worldwide and 25% in the U.S.Q2 2024 EPS increased 68% to $3.28 on a re...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
